Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

被引：0

作者：

Liu, Qingran ^{[1
]}

Li, Jinpeng ^{[2
]}

Chen, Hua ^{[2
]}

Song, Jinlong ^{[2
]}

机构：

[1] Shandong First Med Univ, Binzhou Peoples Hosp, Dept Intervent Med, Binzhou, Shandong, Peoples R China

[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Intervent Therapy 1, Jinan 250117, Shandong, Peoples R China

来源：

HEPATOLOGY | 2025年 / 81卷 / 03期

关键词：

D O I：

10.1097/HEP.0000000000001215

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：E101 / E102

页数：2

共 50 条

[1] Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa, Ciro
Cabibbo, Giuseppe
Fulgenzi, Claudia Angela Maria
Battaglia, Salvatore
Enea, Marco
Scheiner, Bernhard
D'Alessio, Antonio
Manfredi, Giulia F.
Stefanini, Bernardo
Nishida, Naoshi
Galle, Peter R.
Schulze, Kornelius
Wege, Henning
Ciccia, Roberta
Hsu, Wei-Fan
Vivaldi, Caterina
Wietharn, Brooke
Lin, Ryan Po-Ting
Pirozzi, Angelo
Pressiani, Tiziana
Dalbeni, Andrea
Natola, Leonardo A.
Auriemma, Alessandra
Rigamonti, Cristina
Burlone, Michela
Parisi, Alessandro
Huang, Yi-Hsiang
Lee, Pei-Chang
Ang, Celina
Marron, Thomas U.
Pinter, Matthias
Cheon, Jaekyung
Phen, Samuel
Singal, Amit G.
Gampa, Anuhya
Pillai, Anjana
Roehlen, Natascha
Thimme, Robert
Vogel, Arndt
Soror, Noha
Ulahannan, Susanna
Sharma, Rohini
Sacerdoti, David
Pirisi, Mario
Rimassa, Lorenza
Lin, Chun-Yen
Saeed, Anwaar
Masi, Gianluca
Schoenlein, Martin
von Felden, Johann
HEPATOLOGY, 2024,
[2] Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa, Ciro
Cabibbo, Giuseppe
Pinato, David J.
HEPATOLOGY, 2025, 81 (03) : E103 - E104
[3] Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa, Ciro
Cabibbo, Giuseppe
Fulgenzi, Claudia Angela Maria
Battaglia, Salvatore
Enea, Marco
Scheiner, Bernhard
D'Alessio, Antonio
Manfredi, Giulia F.
Stefanini, Bernardo
Nishida, Naoshi
Galle, Peter R.
Schulze, Kornelius
Wege, Henning
Ciccia, Roberta
Hsu, Wei-Fan
Vivaldi, Caterina
Wietharn, Brooke
Lin, Ryan Po-Ting
Pirozzi, Angelo
Pressiani, Tiziana
Dalbeni, Andrea
Natola, Leonardo A.
Auriemma, Alessandra
Rigamonti, Cristina
Burlone, Michela
Parisi, Alessandro
Huang, Yi-Hsiang
Lee, Pei-Chang
Ang, Celina
Marron, Thomas U.
Pinter, Matthias
Cheon, Jaekyung
Phen, Samuel
Singal, Amit G.
Gampa, Anuhya
Pillai, Anjana
Roehlen, Natascha
Thimme, Robert
Vogel, Arndt
Soror, Noha
Ulahannan, Susanna
Sharma, Rohini
Sacerdoti, David
Pirisi, Mario
Rimassa, Lorenza
Lin, Chun-Yen
Saeed, Anwaar
Masi, Gianluca
Schoenlein, Martin
von Felden, Johann
HEPATOLOGY, 2025, 81 (03) : 837 - 852
[4] Early hepatic decompensation is the main driver of mortality in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib
Cabibbo, G.
Celsa, C.
Battaglia, S.
Enea, M.
Di Maria, G.
Grova, A.
Ciccia, R.
Manfredi, G. F.
Iavarone, M.
Vogel, A.
Singal, A. G.
Reig, M.
Pinato, D. J.
Camma, C.
DIGESTIVE AND LIVER DISEASE, 2025, 57 : S21 - S22
[5] Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Celsa, Ciro
Cabibbo, Giuseppe
Fulgenzi, Claudia
Scheiner, Bernhard
Battaglia, Salvatore
D'Alessio, Antonio
Manfredi, Giulia
Stefanini, Bernardo
Nishida, Naoshi
Galle, Peter R.
Schulze, Kornelius
Wege, Henning
Ciccia, Roberta
Hsu, Wei-Fan
Vivaldi, Caterina
Wietharn, Brooke
Lin, Po-Ting
Pirozzi, Angelo
Pressiani, Tiziana
Dalbeni, Andrea
Natola, Leonardo Antonio
Auriemma, Alessandra
Rigamonti, Cristina
Burlone, Michela Emma
Parisi, Alessandro
Huang, Yi-Hsiang
Lee, Pei-Chang
Ang, Celina
Marron, Thomas
Pinter, Matthias
Cheon, Jaekyung
Chon, Hong Jae
Phen, Samuel
Singal, Amit
Gampa, Anuhya
Pillai, Anjana
Thimme, Robert
Vogel, Arndt
Soror, Noha
Ulahannan, Susanna V.
Sharma, Rohini
Sacerdoti, David
Pirisi, Mario
Rimassa, Lorenza
Lin, Chun-yen
Saeed, Anwaar
Roehlen, Natascha
Masi, Gianluca
Schoenlein, Martin
Von Felden, Johann
JOURNAL OF HEPATOLOGY, 2024, 80 : S51 - S52
[6] Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world
Zhang, Junwei
Fang, Jinyu
Xun, Ziyu
Xu, Yiyao
Lu, Xin
Zhao, Haitao
HEPATOLOGY, 2022, 76 (04) : E84 - E85
[7] Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Cabibbo, Giuseppe
Celsa, Ciro
Battaglia, Salvatore
Enea, Marco
Di Maria, Gabriele
Grova, Alessandro
Ciccia, Roberta
Manfredi, Giulia F.
Iavarone, Massimo
Vogel, Arndt
Singal, Amit G.
Reig, Maria
Pinato, David J.
Camma, Calogero
CLINICAL CANCER RESEARCH, 2025, 31 (03) : 543 - 550
[8] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Esmail, Abdullah
Xu, Jiaqiong
Burns, Ethan A.
Abboud, Karen
Sheikh, Ali
Umoru, Godsfavour
Gee, Kelly
Wiechmann, Catherine
Zhang, Yuqi
Abdelrahim, Maen
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
[9] Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
Hsu, Chiun
Ducreux, Michel
Zhu, Andrew X.
Qin, Shukui
Ikeda, Masafumi
Kim, Tae-You
Galle, Peter R.
Finn, Richard S.
Chen, Ethan
Ma, Ning
Hu, Youyou
Li, Lindong
Cheng, Ann-Lii
LIVER CANCER, 2023, 12 (01) : 44 - 56
[10] Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Wang, Chia-Chi
Kao, Jia-Horng
HEPATOLOGY, 2023, 77 (04) : E82 - E83

← 1 2 3 4 5 →